Description
Contents
Salbutamol/Ipratropium
Indications/Uses
COMBIVENT nebuliser solution in unit dose vials are indicated for the management of reversible bronchospasm associated with obstructive airway diseases in patients who require more than a single bronchodilator.
Dosage/Direction for Use
Patients with hepatic or renal impairment: COMBIVENT has not been studied in patients with hepatic or renal insufficiency. It should be used with caution in those patient populations.
Paediatric population: Because of insufficient information in children COMBIVENT is not indicated for paediatric patients.
Patients should be advised to consult a physician or the nearest hospital immediately in the case of acute or rapidly worsening dyspnoea if additional inhalations of COMBIVENT do not produce an adequate improvement.
If higher than recommended doses of COMBIVENT are required to control symptoms, the patient’s therapy plan should be reviewed.
In asthma, concomitant anti-inflammatory therapy should be considered.
Paediatric population: Because of insufficient information in children COMBIVENT is not indicated for paediatric patients.
Patients should be advised to consult a physician or the nearest hospital immediately in the case of acute or rapidly worsening dyspnoea if additional inhalations of COMBIVENT do not produce an adequate improvement.
If higher than recommended doses of COMBIVENT are required to control symptoms, the patient’s therapy plan should be reviewed.
In asthma, concomitant anti-inflammatory therapy should be considered.
*The product images shown are for illustration purposes only and may not be an exact representation of the product.
